Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.
Abu Sabbah T, Theurer S, Baba HA, Lueong S, Rashidi-Alavijeh J, Hilser T, Zaun Y, Metzenmacher M, Pogorzelski M, Virchow I, Pretzell I, Kostbade K, Treckmann J, Wiesweg M, Schuler M, Kasper S, Zaun G. Abu Sabbah T, et al. Among authors: virchow i. Eur J Cancer. 2024 Oct;210:114268. doi: 10.1016/j.ejca.2024.114268. Epub 2024 Aug 10. Eur J Cancer. 2024. PMID: 39153343 Free article.
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G, Borchert S, Metzenmacher M, Lueong S, Wiesweg M, Zaun Y, Pogorzelski M, Behrens F, Schildhaus HU, Virchow I, Kasper S, Schuler M, Theurer S, Liffers S. Zaun G, et al. Among authors: virchow i. Eur J Cancer. 2024 Mar;200:113540. doi: 10.1016/j.ejca.2024.113540. Epub 2024 Jan 26. Eur J Cancer. 2024. PMID: 38316065 Free article.
Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.
Zurloh M, Goetz M, Herold T, Treckmann J, Markus P, Schumacher B, Albers D, Rink A, Rosery V, Zaun G, Kostbade K, Pogorzelski M, Ting S, Schmidt H, Stiens R, Wiesweg M, Schuler M, Kasper S, Virchow I. Zurloh M, et al. Among authors: virchow i. J Cancer Res Clin Oncol. 2023 Nov;149(14):12903-12912. doi: 10.1007/s00432-023-05141-y. Epub 2023 Jul 19. J Cancer Res Clin Oncol. 2023. PMID: 37466791 Free PMC article.
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.
Zaun G, Weber M, Metzenmacher M, Wiesweg M, Hilser T, Zaun Y, Liffers S, Pogorzelski M, Virchow I, Eberhardt W, Theurer S, Sabbah TA, Reissig TM, Stuschke M, Kürten C, Hussain T, Lang S, Kasper S, Fendler WP, Herrmann K, Schuler M. Zaun G, et al. Among authors: virchow i. J Nucl Med. 2023 Aug;64(8):1191-1194. doi: 10.2967/jnumed.122.265161. Epub 2023 Jun 15. J Nucl Med. 2023. PMID: 37321823 Free article.
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J, Kasper S, Treckmann JW, Markus P, Schumacher B, Albers D, Wendling J, Ting S, Mende B, Maßmann M, Markus M, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Reissig TM, Liffers ST, Schmid K, Schildhaus HU, Schuler M, Siveke JT, Wiesweg M. Roehrle J, et al. Among authors: virchow i. Oncol Res Treat. 2023;46(4):140-150. doi: 10.1159/000529452. Epub 2023 Jan 31. Oncol Res Treat. 2023. PMID: 36720216 Free article.
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I, Treckmann JW, Prasnikar N, Linden G, Markus P, Schumacher B, Albers D, Herold T, Ting S, Schmidt H, Radunz S, Wiesweg M, Siveke J, Schuler M, Kasper S. Virchow I, et al. Oncol Res Treat. 2023;46(3):89-99. doi: 10.1159/000529012. Epub 2023 Jan 9. Oncol Res Treat. 2023. PMID: 36623497 Free article. Clinical Trial.
Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.
Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Martinelli E, et al. Among authors: virchow i. ESMO Open. 2022 Dec;7(6):100603. doi: 10.1016/j.esmoop.2022.100603. Epub 2022 Nov 8. ESMO Open. 2022. PMID: 36368253 Free PMC article.
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M, Treckmann J, Markus P, Schumacher B, Albers D, Ting S, Mende B, Roehrle J, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Schmid KW, Baba H, Siveke JT, Paul A, Schildhaus HU, Schuler M, Wiesweg M, Kasper S. Maßmann M, et al. Among authors: virchow i. J Cancer Res Clin Oncol. 2023 Jul;149(8):5085-5094. doi: 10.1007/s00432-022-04424-0. Epub 2022 Nov 5. J Cancer Res Clin Oncol. 2023. PMID: 36334155 Free PMC article.
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Markus M, Abendroth A, Noureddine R, Paul A, Breitenbuecher S, Virchow I, Schmid KW, Markus P, Schumacher B, Wiesweg M, Wendling J, Mende B, Siveke JT, Schuler M, Kasper S. Markus M, et al. Among authors: virchow i. J Cancer Res Clin Oncol. 2021 Feb;147(2):579-591. doi: 10.1007/s00432-020-03361-0. Epub 2020 Aug 25. J Cancer Res Clin Oncol. 2021. PMID: 32839836 Free PMC article.
18 results